Chambal Fertilisers and Chemicals (CHAMBLFERT) Q3 24/25 earnings summary

Executive summary

• Standalone EBITDA for Q3 was INR 843 crore, up 16% YoY; PAT was INR 505 crore, up 25% YoY; nine-month standalone EBITDA reached INR 2,619 crore, up 19% YoY; PAT was INR 1,557 crore, up 25% YoY.

• Consolidated Q3 PAT was INR 534 crore, up 16% YoY; nine-month PAT was INR 1,519 crore, up 29% YoY, driven by higher margins at IMACID JV.

• Urea production and sales volumes increased YoY, with improved energy efficiency and timely subsidy receipts of INR 3,350 crore in Q3.

• Launched 12 new products in 9M FY25, including weedicides, fungicides, and insecticides; biologicals segment revenue up 67%.

• CFCL-TERI partnership established a Centre of Excellence for sustainable agriculture solutions.

Financial highlights

• Q3 FY25 standalone revenue was ₹4,918.06 crore, up from ₹4,348.57 crore in Q3 FY24; nine-month revenue was ₹14,197.47 crore.

• Q3 EBITDA up 16% YoY to ₹843 crore; 9M EBITDA up 19% YoY to ₹2,619 crore.

• Q3 PAT up 25% YoY to ₹505 crore; 9M PAT up 25% YoY to ₹1,557 crore.

• Net cash at Q3 end was INR 3,000 crore.

• Gas cost for Q3 was $15.85 per MMBTU (LCV basis).

Outlook and guidance

• TAN plant expected to start commercial production in January 2026, with ramp-up in FY27; timeline shifted due to plant configuration changes, but no cost overrun.

• Focus on expanding biologicals, specialty nutrients, and product portfolio, with new products and partnerships in the pipeline.

• Entry into hybrid and research variety seeds planned for Kharif FY25.

• IMACID phosphoric acid expansion to 7 lakh MT by 2027-28, with $173 million investment.